56 results
424B4
BIXT
Bioxytran, Inc
2 Oct 23
Prospectus supplement with pricing info
11:36am
for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of marketing applications. Most … to the Company’s Stockholders and to achievement of its goals that may be inherent in its compensation programs. The Compensation Committee will review and discuss
424B4
w6tu b7xd
14 Aug 23
Prospectus supplement with pricing info
8:07pm